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Abstract 
 
Major histocompatibility complex class I (MHC-I) molecules play a crucial role in adaptive 
and innate immunity by capturing peptides for presentation to T-cells and natural killer (NK) 
cells, respectively. The termini of these peptides are tethered at opposing ends of the MHC-I 
molecule, although the extent to which other modes of presentation occur is unknown. Here, 
we show that 20% of the human leukocyte antigen (HLA)-B*57:01-restricted peptide 
repertoire comprises N-terminally extended sets characterised by a common motif at position 
(P)-1 to P2. Crystal structures of HLA-B*57:01 presenting N-terminally extended peptides, 
including the immunodominant HIV-1 Gag epitope TW10 (TSTLQEQIGW; residues 240-
249), revealed that the N-terminus protruded from the peptide-binding groove in a conserved 
manner. Notably, the common escape mutant TSNLQEQIGW bound HLA-B*57:01 in the 
canonical fashion and adopted a dramatically different conformation that also impacted 
recognition by killer immunoglobulin-like receptor (KIR)3DL1. These results define a 
previously uncharacterised feature of the HLA-I immunopeptidome with important 
implications for viral immune escape. 
 
Introduction 
 
Human leukocyte antigen class I (HLA-I) molecules are a vital component of cellular immunity, 
presenting endogenous peptide epitopes on the cell surface for scrutiny by CD8+ T-cells and natural 
killer cells (NK cells). These peptides represent a mix of intracellular proteins that have been 
proteolytically degraded and during the course of a viral infection will include epitopes originating 
from the invading pathogen. HLA-I molecules bind compatible peptides via a specialised groove 
capped by a conserved network of residues that form hydrogen (H) bonds with the N- and C-termini 
of the peptide1. The peptide is further anchored at specific pockets spaced along the groove, 
typically at the P2 and P positions for many HLA allotypes 2, 3, 4, 5, 6. The nature of these 
‘anchoring pockets’ differs between HLA-I molecules thus defining their unique peptide repertoires 
6, 7.  
 
The closed-end nature of the HLA-I antigen (Ag)-binding cleft generally constrains the repertoire of 
peptides to 9−11 amino acids in length. Some longer HLA-I-restricted peptides have been 
described, but on account of the conserved polar interaction network with the N- and C-termini in 
the P1 and P  longer peptides are canonically accommodated in the groove by 
adopting a ‘bulged’ conformation, where the central portion of the peptide epitope projects from the 
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groove 8, 9, 10. The T-cell receptor (TCR) binds these bulged regions of the peptide whilst 
simultaneously contacting the HLA-I molecule. Isolated reports have described peptides that 
protrude at the C-terminus from the peptide-binding groove with the P-1 residue acting as an 
alternate C-terminal anchor, although the extent to which this represents a common occurrence 
remains unclear 11, 12. Such non-canonical HLA-I-peptide landscapes are important because they 
potentially form unique contact surfaces for TCR and killer immunoglobulin-like receptor (KIR) 
recognition with attendant implications for disease-relevant immune responses 12, 13, 14. In contrast, 
it is not known whether peptides can protrude from the N-terminus of the HLA-I Ag-binding cleft.  
 
The HLA-B*57:01 allele is associated with slower HIV-1 disease progression 15, 16, 17, 18, 19 and 
autoimmune reactions, including hypersensitivity, to the anti-viral drug abacavir 20, 21, 22. In HIV-1-
infected individuals, the expressed HLA-B*57:01 allomorph elicits robust CD8+ T-cell responses 
that are thought to control viremia. Four epitopes in particular within the p24 Gag protein (TW10, 
IW9, QW9 and KF11) are associated with such protective immunity 16, 23, 24, 25. Cellular immune 
responses against these epitopes drive the selection of amino acid mutations that allow viral escape 
from the immune system 26, 27, 28. A common escape mutation in the p24 Gag epitope TW10 
(TSTLQEQIGW; residues 240-249)TW10 is T242N, which lies at position (P)3 of the epitope 
(T3N) 29, 30, 31, 32. The emergence of this variant coincides with loss of the original CD8+ T-cell 
response in many patients 25, 30 and impaired viremic control, especially after the acquisition of 
compensatory mutations 28, 33. In addition, HLA-B*57:01 is a ligand for members of the KIR3DL1 
family, and there is a strong genetic association across the KIR3DL1-HLA-B*57 axis with delayed 
progression to AIDS 34, 35, 36.  
 
Here, we show that the repertoire of endogenous and viral peptides presented by HLA-B*57:01 
contains sets of both N- and C-terminally extended epitopes. A characteristic motif was identified 
as a signature of N-terminally extended peptides and structural studies revealed a non-canonical 
binding mode whereby the N-terminal residue overhangs the peptide-binding groove of HLA-
B*57:01. This novel mode of peptide binding enables HIV-1 to escape immune recognition via a 
register shift within the TW10 epitope that alters the presented antigenic structure, upon mutation to 
T3N. 
 
Results 
Structure of HLA-B*57:01-TW10 in complex with KIR3DL1 
To extend our previous analysis of KIR3DL1 bound to HLA-B*57:01 presenting a self-peptide, we 
determined the crystal structure of KIR3DL1*001-HLA-B*57:01 in complex with the HIV-1 p24 
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Gag epitope TW10 (TSTLQEQIGW; residues 240-249). Crystals of KIR3DL1-HLA-B*57:01-
TW10 diffracted to a resolution of 2.0 Å and the final model was refined to Rfactor and Rfree values of 
20.3 % and 23.9 %, respectively (Table 1).  
 
The mode of KIR3DL1 recognition of the viral epitope was essentially identical to that of the self-
peptide bound to HLA-B*57:01 37 (Figure 1a).  The three KIR3DL1 domains engaged HLA-
B*57:01 in a conserved orientation with the D0 domain docking at the side and the D1 and D2 
domains docking at the C-terminal end of the peptide binding cleft, above the α1 and α2 helices 
respectively (Figure 1a). The D1 domain interacted with the Bw4 motif on the α1 helix. In the 
course of our analysis, we noted that the TW10 epitope adopted a unique conformation not 
previously observed for HLA-I-peptide complexes. Namely, the N-terminal region of the TW10 
epitope protruded from the Ag-binding cleft and thus did not occupy the A pocket (Figure 1b). 
Instead, the second and third residues of the TW10 epitope were located in the A and B pockets, 
respectively (Figure 1b). Comparison with available HLA-B*57:01-peptide structures 21, 37, 38 
showed that, with the exception of a 0.7 Å shift of Trp167 (not shown), there were minimal 
structural distortions to the peptide-binding cleft that accompanied this previously unobserved 
peptide conformation (r.m.s.d. < 0.25 Å over C positions 1 -180).  Due to the closed nature of the 
peptide-binding groove, the P-1 residue of the peptide projected at a right-angle from the plane of 
the floor of the groove, with the side-chain pointing back along the length of the peptide (Figure 
1c). Contacts between P-1-Thr and HLA-B*57:01 were limited to water-mediated H-bonds between 
Trp167 and the P-1-Thr peptide backbone and van Der Waals interactions between Glu63 and 
Leu163 and the P-1-Thr1 side-chain (Figure 1c). Contacts between the P-1Thr and the rest of the 
peptide included water-mediated H-bonds with P2-Thr and P4-Gln (Figure 1c).  
 
The A pocket is characterised by a highly conserved set of residues including Tyr7 and Tyr171 
which contribute a network of H-bonds that stabilises the N-terminus of the presented peptide.  In 
the HLA-B*57:01-TW10 complex, the P1-Ser residue of the TW10 epitope occupied the A pocket 
of HLA-B*57:01 and, as such, maintained a network of H-bonds with Tyr7 and Tyr171 (Figure 
1d). In so doing, the P1-Ser sidechain was rotated approximately 180° from the canonical 
positioning of a P1 anchored residue. Accordingly, the slippage of TW10 from the groove of HLA-
B*57:01 was accompanied by distortion of the peptide at the P1 residue and not by structural 
distortion of the peptide-binding groove. As peptide repertoire data for HLA-B*57:01 had 
previously demonstrated the P2 anchor preference for Ser or Thr 21 it was conceivable that either 
P2-Ser or P3-Thr could act as N-terminal anchors for TW10. However, the high-resolution structure 
of HLA-B*57:01-TW10 displayed unambiguous electron density across the peptide, thereby 
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indicating that only one conformation of TW10 was present in the crystal lattice. Further, it was 
confirmed by the use of hydrogen-deuterium exchange with mass spectrometry that, compared to 
the peptide free in solution, TW10 adopts a single conformation whilst in complex with B*57:01 
(Figure 2). Thus, the P-1 to P2 residues enable the peptide to extend from the peptide-binding cleft 
of HLA-B*57:01. 
 
N-terminally extended peptides within the HLA-B*57:01 immunopeptidome 
To determine whether N-terminally extended peptides are a general feature of the HLA-B*57:01 
restricted immunopeptidome, we sought to define the range of self-peptides and HIV-Gag epitopes 
presentated by HLA-B*57:01. Peptides were isolated from C1R cells transfected with expression 
constructs for HLA-B*57:01 and HIV-1-Gag and sequenced using tandem mass spectrometry.  This 
data set was: (i) filtered for peptides known to bind the endogenous HLA-I and HLA-II of the 
parental cell line, or bearing the peptide binding motifs of HLA-Cw4 and HLA-B*35:03 
(endogenous HLA-I of C1R cells) (14); and (ii) further augmented with previously defined peptides 
from the immunopeptidome of HLA-B*57:01 (24), which collectively amounted to 11954 peptides 
(Supplementary Table 1).  As previously described, HLA-B*57:01 ligands were predominantly 9-
11 amino acids in length and showed enrichment of S/T/A at the P2 anchor, and aromatic residues 
at the C-terminus (Figure 3) 21. In addition, a number of peptides were identified that contained 
these shorter 9-11 amino acid peptides with an N-terminal extension.   
 
Extended sets of peptides were defined based on the following criteria: i) minimal core sequence of 
7-11 amino acids, ii) maximal sequence > 9 amino acids.  1275 sets of peptides met these criteria, 
of which 17%, 18% and 12% of 9, 10 and 11 residue peptides fell within these criteria and 
possessed only N-terminal extensions, whilst far fewer were purely C-terminally extended (3%, 3% 
and 2% respectively) (Figure 3a). To define the sequence features that were predisposed to N-
terminal extensions, peptides exhibiting N-terminal heterogeneity were aligned based on the 
minimal sequence P1 (Supplementary Table 2). The motif was visualised as a sequence logo 
encompassing P-1 (1 residue N-terminal of P1) to P3 using Icelogo 39.  A similar motif was also 
generated from the P1 to P3 of all 9-11 residue peptides within the HLA-B*57:01 peptide data set 
and aligned at P1 for comparison (Figures 3b and 3c).  Whilst the global HLA-B*57:01 9-11 
amino acid peptide motif shows enrichment of K/I/R at P1, it was observed that N-terminally 
extended peptides were enriched for S/T/A at P1 and P-1.  Given that S/T/A are preferred P2 
anchors for HLA-B*57:01, these residues could potentially be acting as alternate anchor sites in 
longer peptides, resulting in bulged conformations within the peptide-binding groove.  However 
given the appearance of numerous sets where a minimal core sequence was found with several 
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extension lengths (e.g. Set 233: STTSVASSW, TSTTSVASSW, DTSTTSVASSW, 
HDTSTTSVASSW, SHDTSTTSVASSW, SSHDTSTTSVASSW and TASSHDTSTTSVASSW) 
not all of which contained S/T/A at the second residue, it seemed likely that the excess residues 
might overhang the cleft.  Thus, we defined the N-terminal protrusion motif as S/T/A at P-1 to P2. 
 
The TW10 epitope is part of a N-terminally extended set of peptides restricted by HLA-B*57:01 
Of the 11954 peptides used in this analysis 9 were derived from the Gag polypeptide. Amongst the 
Gag derived epitopes, two N-terminally extended epitope sets were observed, QW9 and TW10 
(Figure 4a, Set 33 and Set 500 Supplementary Table 2). The TW10 epitope was the minimal 
peptide observed within its N-terminally extended set that contained multiple extension lengths 
(Figure 4a). To determine the relative abundance of each peptide in the set, we measured the 
extracted ion chromatogram specific for each of the peptides (Figure 4b). The N-terminally 
extended AGTTSTLQEQIGW peptide was the most intense ion and by inference the most 
abundant, followed by TTSTLQEQIGW, GTTSTLQEQIGW and TW10 (Figure 4b). Two longer 
N-terminally extended peptides were also identified (DIAGTTSTLQEQIGW and 
SDIAGTTSTLQEQIGW) at significantly lower levels (Figure 4b). Taken together, our data 
suggest that a common motif characterises N-terminally protruding HLA-B*57:01-restricted 
peptides regardless of self or viral origin. 
 
Structure of HLA-B*57:01 in complex with N-terminally extended self peptides 
To further probe the structural nature of the N-terminal extension motif we investigated three 
epitopes from the self-repertoire of HLA-B*57:01. The selected peptides were TSTTSVASSW 
(UNP Q14679), TSTFEDVKILAF (UNP Q6YHU6) and SSTRGISQLW (UNP A8CG34) each of 
which formed part of a nested set (Supplementary Table 2 Set 233, Set 926 and Set 736 
respectively). Crystals of the refolded HLA-B*57:01-peptide complexes formed in the space group 
P212121 with unit cell dimensions of ~a = 50, b = 82, and c = 110 Å, and diffracted to high 
resolution (Table 1).  
 
All these HLA-B*57:01-peptide complexes adopted the non-canonical conformation observed for 
HLA-B*57:01-TW10. Namely, the P2-Ser of TSTTSVASSW, TSTFEDVKILAF and 
SSTRGISQLW occupied the A pocket, which normally accommodates the N-terminal amide. The 
H-bonding network at the N-terminus of the peptide-binding groove was similarly conserved, with 
the hydroxyl of the P2-Ser maintaining the contacts seen in canonically bound peptides (Figures 
5a-c). Accordingly, the P-1 to P2 motif identified in the repertoire analysis is a common motif that 
enables the peptide to protrude from the N-terminus of HLA-B*57:01. 
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The structural basis of viral escape via the T3N mutation in TW10 
The TW10 epitope undergoes a common and rapid substitution at the N-terminus, namely T3N 
(TSNLQEQIGW), to facilitate HIV-1 immune escape in HLA-B*57:01+ individuals. To address 
this phenomenon at the molecular level, we determined the crystal structure of HLA-B*57:01 in 
complex with the T3N peptide and KIR3DL1 (Table 1). Overall, the contacts between KIR3DL1 
and HLA-B*57:01 were conserved between the TW10 and T3N structures. However, contacts 
between KIR3DL1 and the HLA-bound peptide were markedly different for TW10 and T3N. 
KIR3DL1 formed two contacts with the T3N peptide. The D1 Gly116 bound P7-Gln, whilst Tyr200 
at the D1/D2 hinge-loop bound P8-Ile (Figure 6a). In contrast, KIR3DL1 did not directly contact 
the TW10 peptide. Instead, water-mediated contacts were formed between Tyr200 and the 
backbones of P8-Gly and P9-Trp (Figure 6b). KIR3DL1 therefore interacted differently with 
TW10 and T3N as a result of changes in the bound peptide conformation (detailed below). 
 
The Thr3Asn substitution caused the peptide to adopt a conventional anchoring mode bound to 
HLA-B*57:01 with the A and B pockets occupied by P1-Thr and P2-Ser, respectively (Figure 6c). 
Notably, the HLA-B*57:01-TW10 complex was more stable than the HLA-B*57:01-T3N complex, 
with a melting temperature of 61.8°C compared with 55.0°C in circular dichroism assays 
(Supplementary Figure 1). The inability of Asn3 to occupy the B pocket is consistent with 
previous HLA-B*57:01 peptide elution data in which Asn was not observed as an anchor residue at 
position 2 21. The change in anchoring at P2 shifted the peptide register across all positions except 
the C-terminal anchor and P9-Gly (Figure 6d). Accordingly, the secondary anchor positions also 
differed between TW10 and T3N. Specifically, the TW10 secondary anchors at P3-Leu, P6-Gln and 
P7-Ile were reassigned to P3-Asn, P5-Gln and P6-Glu, respectively, in T3N. Consequently, the P-1-
Thr, P4-Gln and P5-Glu side-chains were considerably solvent exposed in TW10, whereas P4-Leu, 
P5-Gln and P8-Ile were considerably solvent exposed in T3N (Figure 6d). Thus, the Thr3Asn 
mutation shifts the peptide register within the peptide-binding groove, resulting in the presentation 
of an altered peptide conformation to immune cell receptors. 
 
Escape mutants in the TW10 epitope abrogate KIR3DL1 recognition 
To determine whether the T3N escape mutation was able to maintain binding to the inhibitory NK 
cell receptor KIR3DL1, the HLA-B*57:01-TW10 and -T3N complexes were coupled to a CM5 
chip with the anti-HLA monoclonal antibody W6/32 and the affinity to KIR3DL1*001 measured by 
surface plasmon resonance (SPR). The TW10 complex was observed to bind more strongly to 
KIR3DL1 than T3N, with affinities of ~60 μM and ~100 μM respectively (Figure 7a).  
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To assess the impact of mutation within the TW10 epitope on NK cell function, the binding of T3N, 
and a second common TW10 escape variant G9D, was measured. Tetramer binding of HLA 
B*5701-TW10, T3N and G9D to KIR3DL1 transfected HEK293T cells was compared for common 
KIR3DL1 allotypes within the population (*001, *005 and *015). Recognition of the HLA B*57:01 
tetramer was abrogated for the T3N escape mutation across all KIR3DL1 allotypes tested (Figure 
7b). However, the degree of abrogation varied with KIR3DL1 allotype, with KIR3DL1*005 being 
the least sensitive to the G9D mutation (50 % of wild-type binding), and *015 the most sensitive to 
changes in the epitope (Figure 7b).  
 
The relative contribution of the residues of KIR3DL1*001 to the HLA-B*57:01-TW10 and T3N 
interfaces was further probed by mutational analysis. Overall, there were distinct differences in the 
recognition of the HLA-peptide complexes (Figure 7c, d). Looking at these differences by 
KIR3DL1 domain, it was observed that within the D0 domain, the T3N complex was comparatively 
less sensitive to substitution at position F9 than TW10, whilst being more sensitive to substitution at 
F34 (Figure 7c, d). Similarly, clear differences in the recognition by the KIR3DL1 D1 domain 
were noted.  That is, substitution at positions G138 and S140 resulted in significantly different 
recognition of TW10 yet had limited impact on T3N recognition, whilst the L166A mutation was 
sufficient to restore T3N binding to wild-type (TW10) levels (Figure 7c, d). Substitutions across 
the KIR3DL1 D2 domain resulted in comparable contributions from residues Try200, Glu201, 
Ser277, Ser228, Phe276, His278 and Ser279. Contrary to this, Arg277Ala abrogated T3N binding 
whilst improving recognition of TW10. 
 
Taken together, these analyses demonstrate that the viral escape mutant T3N abrogates KIR3DL1 
recognition, with the degree of abrogation dependent upon KIR3DL1 allotype. Furthermore, the 
KIR3DL1 residue Leu166, that sat  proximal to the interface with the peptide, was central to 
dictating the reduced affinity for the escape variant. Thus, whilst the altered peptide conformation 
of T3N results in additional direct contacts to KIR3DL1, it nonetheless serves to limit the 
interaction. Accordingly, whilst the HIV escape mutants within the TW10 epitope evade T-cell 
recognition, they are likely more vulnerable to NK lysis via KIR3DL1 disinhibition.  
 
Discussion 
HLA-II molecules possess open-ended Ag-binding clefts that allow peptides to extend from the 
groove at both the N- and C-termini. In contrast, the N- and C-terminal pockets of HLA-I molecules 
are closed, thereby restricting the bound peptides to a typical length of 9-11 amino acids.  
Nevertheless, longer MHC-I-restricted epitopes have been described that adopt a centrally bulged 
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conformation whilst maintaining the N- and C-terminal anchor residues. In addition, there have 
been isolated reports of peptides with residues overhanging the C-terminal pocket of HLA-A*02:01 
12, 40 and H2-M3 41. It was not clear, however, whether such overhangs could occur beyond the more 
buried N-terminal pocket.  
 
Our comprehensive analysis of the repertoire of peptides naturally presented by HLA B*57:01, 
shows that approximately 27% are clustered into extended-sets, most of which are solely N-
terminally (20 %) extended, whilst the remaining show either C-terminal extensions or a mix of 
extension at both N- and C-termini. We also demonstrate that N-terminally extended peptides are 
accommodated via protrusion from the groove. From the amino acid enrichment data for N-
terminally extended HLA-B*57:01 epitopes and our structure-based insights we can devise rules 
that predict the P-1 overhang. Namely: (i) The peptide should be a minimum of 1 residue longer 
than the minimal epitope length that can be presented; (ii) the P2 residue should be a residue that 
favours binding in the B pocket and (iii) the P1 residue should be smaller than leucine to enable a 
180 rotation within the A pocket. Accordingly, we define a new mechanism that allows MHC-I 
molecules to present lengthy epitopes.  
 
Viruses have developed numerous strategies to evade HLA-mediated immune detection, including 
mechanisms that directly interfere with the presentation of viral epitopes and HLA molecules on the 
cell surface 42, 43, 44. For example, HIV-1 can increase cellular endocytosis of HLA molecules via 
nef 45, 46, limit HLA transcription and peptide processing via tat 47, 48 and suppress TAP-mediated 
peptide transport into the endoplasmic reticulum 49. Under selection pressure from the immune 
system, HIV-1 also mutates rapidly to evade cytotoxic T lymphocyte responses. These epitope-
centric escape mutations typically alter the conformation of exposed residues that interact with the 
T-cell receptor 50, 51, 52, 53 or abrogate peptide presentation via effects on antigen processing or HLA-
I binding 54, 55. Here, we report a novel mode of escape whereby the common T3N mutant exploits 
the P-1 overhang of TW10 and the anchor residue preferences in the A and B pockets to shift the 
register of the peptide within HLA-B*57:01. This structural rearrangement alters the conformation 
of exposed peptide residues to enable immune escape 29, 30, 31, 32.  
 
There has been significant interest in the idea that KIR-dependent recognition of HLA-I can shape 
the nature of viral escape mutations, raising the possibility that NK cells may exert some selective 
pressure on HIV infection 56, 57. However, it is unclear whether the T3N escape variant is able to 
maintain NK cell inhibition via engagement of KIR3DL1. A previous study using surface plasmon 
resonance reported a reduced interaction with T3N presented by HLA-B*57:03 31. In contrast, 
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another study based on tetramer staining of KIR3DL1-transfected cell lines reported no interaction 
58. Although this discrepancy likely reflects the different experimental approaches, it is clear from 
our structural, SPR and tetramer staining data that KIR3DL1 recognises T3N with a reduced 
affinity compared to that of the TW10 epitope bound to HLA-B*57:01. Notably, the degree to 
which binding was reduced was observed in a KIR3DL1-allotype dependent manner. There are also 
well-described C-terminal escape mutations within the TW10 epitope, of which G9D has similarly 
been shown to abrogate KIR3DL1 recognition in a KIR3DL1-allotype dependent manner 59. This is 
in-line with recent reports on KIR3DL1 allomorph specificity60 and suggests that KIR3DL1 
polymorphism may be an important determinant shaping viral fitness. Accordingly, there appears to 
be a molecular tension between the innate and adaptive arms of the immune system as they 
converge to target a common HIV-I determinant presented by HLA-B*57:01. In sum, our structural 
and proteomics analyses reveal a novel mechanism of viral immune escape, whereby HIV-1 
mutates to exploit a previously undescribed mode of peptide presentation by MHC-I. 
 
Methods 
Isolation of MHCI peptide ligands 
C1R transfectants were grown to high density in RPMI 1640 (Thermo Fisher Scientific, Waltham, 
MA) supplemented with 10 % fetal calf serum (FCS; Bovogen Biologicals Pty. Ltd., Melbourne, 
Australia), 7.5 mM HEPES (MP Biomedicals, Eschwege, Germany), 150 g/mL streptomycin 
(Sigma-Aldrich, St. Louis, MO), 150 U/mL benzylpenicillin (CSL, Parkville, Australia), 2 mM L-
glutamine (MP Biomedicals), 76 M -mercaptoethylamine (Sigma-Aldrich) and 150 M non-
essential amino acids (Life Technologies, Carlsbad, CA). Transfectants were maintained under 
hygromycin (0.3 mg/mL) and G418 (0.5 mg/mL) selection. Cells were harvested by centrifugation 
(1200 g, 20 min, 4 C) and snap frozen in liquid nitrogen. Clarified lysates were generated from 5 x 
109 cells using a combination of cryogenic milling and detergent-based lysis. HLA-peptide 
complexes were immunoaffinity-purified from cell lysates using the W6/32 monoclonal antibody in 
solid phase as described previously 61, 62. Bound complexes were eluted by acidification with 10 % 
acetic acid and fractionated using a 4.6 mm internal diameter x 100 mm long monolithic reversed-
phase (RP) C18 high performance liquid chromatography (HPLC) column (Chromolith SpeedROD; 
Merck Millipore, Darmstadt, Germany) with the ÄKTAmicro™ HPLC system (GE Healthcare, 
Little Chalfont, UK). The mobile phase consisted of buffer A (0.1 % trifluoroacetic acid; Thermo 
Fisher Scientific) and buffer B (80 % acetonitrile, 0.1 % trifluoroacetic acid; Thermo Fisher 
Scientific). HLA-peptide mixtures were loaded onto the column at a flow rate of 1 mL/min with 
separation based on a B gradient of 2−40% for 4 min, 40−45% for another 4 min and a final rapid 2 
min increase to 100%. Fractions (500 µL) were collected, vacuum-concentrated to 10 µL and 
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diluted in 0.1% formic acid to reduce the acetonitrile concentration. The Gag plasmid was a kind 
gift from Johnson Mak (Deakin University, Melbourne Australia).  
 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) sequencing of MHC-I-bound 
peptides 
For LC-MS/MS acquisition, peptide-containing fractions were loaded onto a microfluidic trap 
column packed with ChromXP C18-CL 3 μm particles (300 Å nominal pore size; equilibrated in 
0.1% formic acid/ 2% acetonitrile) at 5 μl/min using a NanoUltra cHiPLC system (Eksigent). An 
analytical (75 μm x 15cm ChromXP C18-CL 3μm, 120A, Eksigent) microfluidic column was 
switched in line and peptides separated using linear gradient elution 0-30% buffer B (80% 
acetonitrile, 0.1% formic acid) over 50 min and 30-80% over 5 min flowing at 300 nL/min. 
Separated peptides were analysed using an AB SCIEX 5600+ TripleTOF mass spectrometer 
equipped with a Nanospray III ion source and accumulating up to 20 MS/MS spectra per second. 
The following instrument parameters were used: ion spray voltage (ISVF) was set at 2400 V, 
curtain gas (CUR) at 25 L/min, ion source gas(GS1) at 10 L/min and an interface heater 
temperature (IHT) setting of 150 ºC. MS/MS switch criteria included ions of m/z >200 amu, charge 
state +2 to +5, intensity >40 cps and the top 20 ions meeting this criterion were selected for MS/MS 
per cycle. The instrument was calibrated every four LC runs using [Glu1]-Fibrinopeptide B 
standard as per manufacturer’s instructions. 
 
LC-MS/MS data was searched against the human proteome (UniProt/SwissProt v2014_10) 
and the HIV NL4-3-gag and AD8-env sequence using ProteinPilot™ software (version 4.5, 
SCIEX). A 5% FDR cut-off was applied. Peptides known to bind the endogenous MHCI of C1R 
cells (HLA-C*04:01 and HLA-B*35:03) 14 and those identified as binders of MHCII in similar 
MHCII isolations in the laboratory and commonly observed contaminants were removed from the 
data set prior to subsequent analysis of HLA-B*57:01 peptide ligands. 
 
Protein expression and purification 
The HLA-B*57:01 and β2-microglobulin genes were sub-cloned into the pET-30 expression vector 
and expressed separately into inclusion bodies in E. coli prior to refolding and purification as 
described previously 63. Briefly, HLA-B*57:01 was refolded by rapid dilution in a solution 
containing 100 mM Tris-HCl pH 8.0, 400 mM L-arginine-HCl, 5 mM reduced glutathione, and 0.5 
mM oxidized glutathione in the presence of β2-microglobulin the appropriate peptide. The refolded 
HLA-B*57:01 complex was purified by anion exchange and size exclusion chromatography. 
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KIR3DL1*001 (residues 1 – 299) was sub-cloned into the pHLSec mammalian expression vector 
with N-terminal 6xHis and secretion tags. KIR3DL1 was expressed and secreted from transiently 
transfected HEK 293S cells and harvested from the culture media after three by nickel affinity and 
gel filtration chromatography using an S200 16/60 column (GE Healthcare) in 10 mM Tris pH 8.0, 
300 mM NaCl. Purified KIR3DL1 was then concentrated to 15 mg/mL and deglycosylated with 
endoglycosidase H (New England Biolabs, Ipswich, MA). The extent of deglycosylation was 
monitored by SDS-PAGE prior to crystallization trials. For surface plasmon resonance studies, a 
similar construct of KIR3DL1*001 was prepared in the pFastBac vector and expressed from Hi-5 
insect cells (Invitrogen, Carlsbad, CA). KIR3DL1 was purified as above excluding the 
endoglycosidase H deglycosylation step. 
 
Hydrogen/deuterium Exchange and analysis by LC-MS.  
A sample containing 5 μg (0.1 nmol) of peptide or protein complex containing peptide was diluted 
24-fold with 50 mM Tris and 50 mM NaCl dissolved in D2O (Cambridge Isotope Laboratories) at 
25 °C to label the sample. The deuteration reaction was quenched at 10 seconds by adding an equal 
volume of 100 mM NaH2PO4 (pH 2.4) and quickly frozen in a dry ice−ethanol bath. The frozen 
sample was quickly thawed and immediately injected onto a micropeptide trap column connected to 
a C18 HPLC column coupled to a Bruker Micro quadrupole time of flight mass spectrometer. The 
HLA-bound peptide was separated using a 12 min gradient of 10−45% acetonitrile at a flow rate of 
50 μL/min. The micropeptide trap and C18 HPLC column were immersed in ice to minimize back 
exchange. Because the mass of a peptide increases by one for every amide hydrogen atom 
exchanged with deuterium, the amount of deuterium can be determined by comparing the mass of 
the labelled peptide with the mass of the same peptide without the label. The centroid mass of each 
peptide was determined using the software package MagTran 64.  
 
Crystallisation, data collection, structure determination and refinement 
The peptide sequences crystallised in complex with HLA-B*57:01 are summarized in Table 2. 
HLA-B*57:01 binary and ternary complexes with KIR3DL1*001 were concentrated to ~ 10 mg/mL 
and crystallized at 294 K by the hanging-drop vapour-diffusion method. Binary complexes (TW10, 
TST-SW10, AST, TSA and YW10) crystallised from a solution comprising 12 -20 % PEG 4000, 
0.2 M ammonium acetate and 0.1 M tri-sodium citrate pH 5.4 – 5.6. Ternary complexes (T3N, 
SW10 and TAT) crystallised from a solution comprising 16% PEG 3350, 2% tacsimate pH 5.0 and 
0.1M tri-sodium citrate pH 5.6. Prior to data collection, crystals were equilibrated in reservoir 
solution with 10% glycerol added as a cryoprotectant and then flash-cooled in a stream of liquid 
nitrogen at 100 K. Data sets were collected at the MX2 beamline (Australian Synchrotron, Victoria). 
 13 
The data were recorded on a Quantum-315 CCD detector and were integrated and scaled using 
MOSFLM and SCALA from the CCP4 program suite 65, 66, 67. Details of the data processing 
statistics are summarised in Table 1. The crystal structures were solved by molecular replacement, 
as implemented in PHASER 68 with HLA-B*57:01-LF9 used as the search model (Protein Data 
Bank accession number: 2RFX). Refinement of the models proceeded with iterative rounds of 
manual building in COOT 69 and refinement in PHENIX 70. The structures were validated with 
MOLPROBITY 71. Refinement statistics are summarised in Table 1. Coordinates and structure 
factors were deposited in the Protein Data Bank under accession numbers XXXX.  
 
Surface Plasmon Resonance  
Surface Plasmon Resonance (SPR) experiments were conducted at 298 K on a Biacore 3000 
instrument using HBS buffer (10 mM HEPES-HCl (pH 7.4), 150 mM NaCl, and 0.005% surfactant 
P20 supplied by GE Healthcare). The HLA class I-specific antibody W6/32 was immobilized on a 
CM5 chip via amine coupling. The pHLA complexes were captured by W6/32 creating a surface 
density of approximately 700 response units (RU). Concentrations of KIR3DL1*001 (2.37 to 
300µM) were injected over the captured pHLA at 5 µl/min. The final response was calculated by 
subtracting the response of W6/32 alone from the KIR3DL1*001-pHLA-B*5701 complex. The 
equilibrium data were analyzed using GraphPad Prism. The data are representative of two 
independent experiments with error bars representing standard error. 
 
Transfection studies 
FLAG tagged KIR3DL1*001 was cloned into the pEF6 vector. Specific nucleotide residues were 
mutated using the QuikChange II Site Directed Mutagenesis Kit (Stratagene) according to the 
manufacturer's instructions. These constructs were introduced into HEK293T cells using FuGene® 
6 transfection reagent (Roche) according to the manufacturer's instructions. After 48 hours, the cells 
were harvested and stained with anti-FLAG (clone M2, Sigma Aldrich) antibody or with tetramer 
for 30 minutes at 4°C. The cells were then washed and analysed on a Fortessa flow cytometer (BD 
Biosciences). Analysis of cell surface expression as assessed by staining with anti-FLAG mAb 
showed that the introduction of the mutations had no substantial effect on expression (data not 
shown). All transfection data are representative of two independent experiments. 
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FIGURE LEGENDS: 
 
Figure 1: HLA-B*57:01 in complex with the TW10 peptide. (a) The overall structure of KIR3DL1 
in complex with HLA-B*57:01-TW10. (b)  Cartoon representation of the crystal structure of HLA 
B*57:01 (light grey) complexed with the TW10 peptide-TSTLQEQIGW (pink) shown against the 
α1 helix of the HLA and oriented N-C terminal from left. (c). Orientation of the protruding Thr 
residue at P-1 and (d) The conserved hydrogen bonding network at the N-terminal end of the HLA 
B*57:01 is maintained to Ser at P1. Hydrogen bonds are displayed as blue dashed lines. 
 
Figure 2: Hydrogen/deuterium exchange for the TW10 peptide in complex with HLA-B*57:01 and 
free in solution. (a) Peptide in complex with HLA-B*57:01 at 0 seconds showing the normal 
isotopic distribution for a singly charged peptide (b) The peptide in complex with HLA-B*57:01 
after 10 seconds incubation in D2O showing a single Gaussian distribution indicative of a single 
bound conformation and (c) the peptide free in a solution of D2O for 10 seconds showing a bimodal 
distribution suggesting multiple conformations in solution. 
 
Figure 3: (a) Length distribution of HLA-B*57:01 ligands, showing those classified as part of 
nested sets.  Peptides within the nested sets are then further broken down into the following 
categories: i. peptides that have been identified as having versions that are extended at the N 
terminus, but do not have C-terminally extended versions (blue, N terminally extended), ii. peptides 
that have been identified as having versions that are extended at the C terminus, but do not have N-
terminally extended versions (red, C terminally extended), iii. peptides that have been identified as 
having versions that are extended at the N terminus, but also have C terminally extended versions 
(green, N or C terminally extended), iv. peptides that have been identified with versions that are 
extended at both the N and C terminus but not at either terminus alone (purple, N and C terminally 
extended), and v. peptides that are the maximal sequence of an extended set. Peptides that were not 
classified as part of an extended set are shown in orange, however it should be noted that extended 
sets were defined as having a minimal sequence of <12 amino acids to minimise ambiguity during 
motif analysis, thus peptides of 12 amino acids or greater that are not part of extended sets as 
defined but have extended versions exist within this category. Percentage values show the 
percentage of 9, 10 and 11 amino acid peptides that are part of extended sets and are extended at the 
N terminus alone. (b) and (c) Sequence logos showing the percentage difference in abundance of 
amino acids at each location in the N-terminal portion of HLA-B*57:01 ligands in comparison to 
their abundance in the human proteome. Logos were generated from the N-terminal portion of all 9-
11 residue peptides in the HLA-B*57:01 data set (n=8268), aligned based on first residue 
assignment of P1 (b) and from the N-terminal portion of the maximal sequences of nested sets 
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containing purely N-terminal extensions, aligned based on the minimal sequences of the nested set 
and possessing C-terminal aromatic anchors (n=972) (c). Sequence logos were generated using the 
iceLogo stand alone version 39. 
 
Figure 4: The HIV-1 Gag repertoire of HLA-B*57:01. (a)  HIV-1 Gag epitopes presented by HLA-
B*57:01. The QW9 and TW10 epitopes form part of N-terminally extended sets. (b) Relative levels 
of N-terminally extended variants compared to the HIV-Gag TW10 epitope. Error bars represent 
mean with SD; n =3. 
 
Figure 5: Cartoon representation of the crystal structure of HLA-B*57:01 (light grey) complexed 
with the TSTFEDVKILAF peptide (blue). (a) HLA-B*57:01 complexed with the TSTFEDVKILAF 
peptide shown against the α1 helix of the HLA and oriented N–C terminal from left. (b) The 
network of direct and water-mediated hydrogen bonds (dark blue dashed lines) around the 
protruding P-1 residue showing the interaction of P-1-Thr with Trp167 and Asn66 of the HLA. (c) 
The network of conserved hydrogen bonds at the N-terminus of the HLA-B*57:01 peptide-binding 
groove showing the P1-Ser1 side-chain replacing contacts normally mediated by the N-terminus of 
the peptide. 
 
Figure 6: Comparison of the TW10 and T3N ternary complex structures with KIR3DL1*001 (a) 
The interactions between KIR3DL1 (teal) and the T3N peptide (blue). (b) The interactions between 
KIR3DL1 (teal) and the TW10 peptide (magenta). (c) Cartoon representation of the crystal structure 
of HLA-B*57:01 (light grey) complexed with the T3N peptide-TSNLQEQIGW (dark blue) shown 
against the α1 helix of the HLA and oriented N-C terminal from left. Hydrogen bonds are displayed 
as blue dashed lines. (d) Overlay of the TW10 (pink) and T3N (dark blue) peptide conformations. 
 
Figure 7: HLA B*57:01 TW10 and T3N binding to KIR3DL1 (a) SPR based affinity 
measurements of the interaction between KIR3DL1*001 and (i) B57:01 TW10 and (ii) B*57:01 
T3N complexes (b) Staining of KIR3DL1 allotypes with HLA B*57:01 TW10 (blue) and T3N 
(grey) tetramers (0.2 μg each), normalised to TW10 binding (c) HLA B*57:01 TW10 (blue) and 
T3N (grey) tetramer staining of HEK293 cells transfected with KIR3DL1*001 and a panel of 
KIR3DL1*001 interface residue mutants, normalised to TW10 tetramer binding to KIR3DL1*001 
or (d) to the respective tetramer binding of KIR3DL1*001 transfectants.  
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Supplementary Figure 1: Circular dichroism readings taken at 222nm over a temperature range of 
20–90 °C for the HLA-B*57:01-TW10 complex (a) and the HLA-B*57:01-T3N complex (b). Tm 
was calculated by fitting a sigmoidal dose-response curve and taking the IC50 value of the curve. 
 
Supplementary Table 1: List of all peptides isolated from HLA-B*57:01 and their source 
proteins.  Peptides contained in nested sets are indicated.  Peptides considered unlikely to be 
true HLA-B*57:01 ligands due to lack of conformation to consensus motif are noted. 
 
Supplementary Table 2: 1000 purely N-terminally extended nested sets of peptides 
identified in isolates from HLA-B*57:01. Peptides considered unlikely to be true HLA-B*57:01 
ligands due to lack of conformation to consensus motif are noted. Alignment of sets is based 
on P1 of the minimal peptide except where the minimal peptide is 7 or 8 amino acids in length 
(in which case residue 1 is P3 or P2 respectively).  Likely misaligns due to non-favourable 
amino acid at P2, and likely contaminants are noted.  Maximal peptides used to describe the 
N-terminal extension motif are indicated. Peptides for which structures have been resolved 
and the register of the overhang observed are noted. 
 
Supplementary Table 3: Extended sets containing C-terminal or N and C-terminal 
extensions. Peptides considered unlikely to be true HLA-B*57:01 ligands due to lack of 
conformation to consensus motif are noted. 
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